Ranbaxy’s $500 Million Settlement Includes Criminal Penalties
This article was originally published in The Pink Sheet Daily
The generic drug maker’s Ranbaxy USA Inc. subsidiary pleads guilty to seven felony counts brought in connection with a longstanding government investigation into data integrity issues and manufacturing violations at two Indian sites, but while the settlement eliminates some worries for the firm, operations still face the weight of a FDA consent decree.
You may also be interested in...
US FDA's Rush Following Novartis' Delay Suggests Strong Displeasure With Handling Of Zolgensma Data Manipulation
Early release of inspection findings is unusual, signaling likelihood that Novartis will face tough scrutiny of its actions, and perhaps stiff fines because of the fraud.
Gene therapy should remain on the market, FDA says, but Novartis could face civil or criminal penalties. Firm knew of problems before approval.
Baxter resolves US plant’s GMP whistleblower allegations for just $18m, a bargain compared to the $750m GlaxoSmithKline paid in 2010 and the $500m Ranbaxy paid in 2013. One reason: it was more narrowly focused.